



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>		
			Application Number	10/010942	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Filing Date	December 6, 2001	
			First Named Inventor	Guriq Basi et al.	
			Art Unit	1647 1649	
			Examiner Name	E.J. Nichols Ballard	
			Attorney Docket Number	ELN-002	
Sheet	1	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	606	5,593,846	01-14-1997	Schenk et al.	
	607	5,837,672	11-17-1998	Schenk et al.	
	610	2002/0102261 A1	08-01-2002	Raso	
	611	2002/0136718 A1	09-26-2002	Raso	
	612	2003/0147882 A1	08-07-2003	Solomon et al.	
	616	5,096,706	03-17-1992	Flint	
	630	6,750,324	06-15-2004	Schenk et al.	
	631	6,787,637	09-07-2004	Schenk et al.	
	638	4,912,206	03-27-1990	Goldgaber et al.	
	639	6,875,434	04-05-2005	Schenk	
	640	6,866,849	03-15-2005	Schenk	
	641	6,866,850	03-15-2005	Schenk	
	642	6,818,218	11-16-2004	Schenk	
	643	6,761,888	07-13-2004	Schenk	
	644	6,743,427	06-01-2004	Schenk	
	645	5,576,184	11-19-1996	Better et al.	
	649	2004/0241164 A1	12-02-04	Bales et al.	
✓	650	2004/0265919 A1	12-30-04	Vanderstichlele et al.	
KAB	651	5,589,154	12-31-96	Anderson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
KAB	608	WO 00/72880 A2, A3	12-07-2000	NeuroLab Limited		
	609	WO 00/72876 A2, A3	12-07-2000	NeuroLab Limited		
	623	WO 00/23082 A1	04-27-2000	Yeda Research & Develop.		
✓	624	WO 02/088306 A2	11-07-2002	Eli Lilly & Co.		
KAB	625	WO 02/088307 A2	11-07-2002	Eli Lilly & Co.		
KAB	632	PCT Search Report for application PCT/US04/02858	N/A	NeuroLab Limited		
KAB	646	WO 04/031400 A2	04-15-2004	NorthWestern Univer.		
KAB	647	WO 04/013172 A2, A3	02-12-2004	Innogenetics N.V.		
KAB	652	WO 2004/080419 A3	09-23-2004	NeuroLab Limited et al.		
✓	653	PCT Search Report for application PCT/US03/07715	N/A	NeuroLab Limited et al.		

DO NOT PRINT (NO DATE)  
9/22/05 KAB

Examiner Signature	<i>Himberly Ballard</i>	Date Considered	9/22/05
--------------------	-------------------------	-----------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>			
		Application Number	10/010942		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	December 6, 2001		
		First Named Inventor	Guriq Basi <i>et al.</i>		
		Art Unit	1647/1649		
		Examiner Name	C.J. Nichols Ballard		
		Attorney Docket Number	ELN-002		
Sheet	2	of	4		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	593	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <i>Nature</i> , 408(6815):975-979 (2000).	
	594	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <i>Nature</i> , 408(6815):979-982 (2000).	
	595	MATTSON, "Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives," <i>Physiol Rev.</i> , 77(4):1081-132 (1997).	
	596	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <i>Adv Clin Pathol.</i> , 4(2):77-85 (2000).	
	597	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <i>Nature</i> , 408(6815):982-985 (2000).	
	598	SCHENK et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <i>DNA Cell Biol.</i> , 20(11):679-81 (2001).	
	599	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <i>Trends Cell Biol.</i> , 8(11):447-53 (1998).	
	600	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <i>J Neuropathol Exp Neurol.</i> , 59(1):11-17 (2000).	
	601	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <i>Ann N Y Acad Sci.</i> , 920:206-8 (2000).	
	602	SOTO et al., "Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy," <i>Nature Medicine</i> , 4(7):822-826 (1998).	
	603	VEHMAS et al., "beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology," <i>DNA Cell Biol.</i> , (11):713-721 (2001).	
	604	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <i>Neurology</i> , 57(5):801-5 (2001).	
	605	SMALL et al., "Alzheimer's disease and Abeta toxicity: from top to bottom," <i>Nat Rev Neurosci.</i> , 2(8):595-8 (2001).	
KAB	613	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F beta-Amyloid Precursor Protein and Alzheimer's Disease," <i>J. Neuroscience</i> , 16(18):5795-5811 (1996).	

Examiner Signature	K. Ballard	Date Considered	9/22/05
--------------------	------------	-----------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>		
			Application Number	10/010942	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Filing Date	December 6, 2001	
			First Named Inventor	Guriq Basi et al.	
			Art Unit	4647-1649	
			Examiner Name	G.J. Nichols Ballard	
			Attorney Docket Number	ELN-002	
Sheet	3	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	614	IRIZARRY et al., "A $\beta$ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
	615	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999).	
	617	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	
	618	BARD et al., "Epitope and isotype specificities of antibodies to $\beta$ -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).	
	619	LEVERONE et al., "A $\beta$ 1-15 is less immunogenic than A $\beta$ 1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting," <u>Vaccine</u> , 21:2197-2206 (2003).	
	620	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- $\beta$ Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).	
	621	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).	
	622	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991).	
	626	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	627	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979).	
	628	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).	
	629	BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <u>Renal Failure</u> , 15(3):365-371 (1993).	
	633	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	634	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).	
	635	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970).	
KAB	636	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V <sub>L</sub> -V <sub>H</sub> and V <sub>L</sub> -V <sub>L</sub> domain dimers," <u>PNAS</u> , 82:4592-4596 (1985).	

Examiner Signature	K. Ballard	Date Considered	9/22/05
--------------------	------------	-----------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
		Application Number	10/010942
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	December 6, 2001
		First Named Inventor	Guriq Basi <i>et al.</i>
		Art Unit	1047 1649
		Examiner Name	G.J. Nichols <i>Ballard</i>
		Attorney Docket Number	ELN-002
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	637	VERSHIGORA A. E. OBRUCHAYA IMMUNOLOGIYA, pages 35, 229-231 and 152-153.	
KAB	648	Zlokovic BV, <i>et al.</i> , <i>Proc Natl Acad Sci USA</i> , 1996 Apr 30;93(9):4229-34.	

NO DATE,  
PUBLISHER

NO TITLE  
9/22/05  
KAB

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Kris Ballard</i>	Date Considered	1/22/05
--------------------	---------------------	-----------------	---------